Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Nov 1.

Published in final edited form as: Semin Nucl Med. 2016 Sep 3;46(6):502–506. doi: 10.1053/j.semnuclmed.2016.07.004

Fig. 2 — Maximum intensity projection FDG PET images show baseline castrate-sensitive state with hypermetabolic metastatic lesions (A), which responded favorably to androgen deprivation therapy with decline in metabolic activity of metastatic lesions (B).

Fig. 2 — Maximum intensity projection FDG PET images show baseline castrate-sensitive state with hypermetabolic metastatic lesions (A), which responded favorably to androgen deprivation therapy with decline in metabolic activity of metastatic lesions (B).